GROWTH STOCK ANALYZER Open the app
Growth Stock Analyzer › OGN growth analysis
Growth stock analysis · updated 2026-07-28

Organon & Co. (OGN) growth stock analysis

Is Organon & Co. a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.

Not right now by CANSLIM
49
Growth score
80
RS rating
#1,239
Rank
2/6
Traits passed
49/99
Growth score · 1239th of 4,892 US stocks
CANSLI
Six growth traits, scored 1–99

What the data says about OGN

As of the 2026-07-28 close, OGN scores 49 out of 99 on our growth-stock rating, a weak growth-stock profile. That ranks it 1239th of 4,892 rated US stocks, the top 25% of the market.

Its strongest trait is N (new highs & catalysts) at 88, and its weakest is C (current quarterly earnings) at 9. OGN clears 2 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.

On price, OGN carries a strong Relative Strength rating of 80, meaning it has outperformed about 80% of the market over the past year.

Underneath the score: quarterly earnings up 67% year over year, sales down 4%, trading 0% below its 52-week high.

OGN growth-trait breakdown

The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.

C
Current quarterly earnings
most recent EPS growth vs. a year ago
9
A
Annual earnings growth
multi-year earnings trend
13
N
New highs & catalysts
proximity to new 52-week highs
88
S
Supply & demand
volume behind the move vs. share supply
28
L
Leader or laggard
Relative Strength within its group
55
I
Institutional sponsorship
fund accumulation and 13F ownership
69

Is OGN a growth stock?

Not right now by CANSLIM

On today’s data OGN does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.

🔒 Stronger growth stocks than OGN

The stocks ranking above OGN today, the growth leaders you’d weigh against it.

See today’s top ranks for free →

🔒 OGN price history & buy range

Where OGN sits in its base, its 52-week path, and the trait trend over the past year.

Open the full OGN profile →

See where OGN ranks among every US growth stock

Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.

Open the app, free through September 1

OGN as a growth stock, frequently asked

Is OGN a good growth stock?

Not right now by CANSLIM. On today’s data OGN does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.

What is OGN's growth score?

Organon & Co. (OGN) scores 49 out of 99 on our growth-stock rating as of the 2026-07-28 close, ranking 1239th of 4,892 rated US stocks.

Does OGN have strong earnings growth?

OGN's most recent quarterly earnings were up about 67% year over year, with sales down 4%.

How strong is OGN's price performance?

OGN has a Relative Strength rating of 80, meaning it has outperformed roughly 80% of the US market over the trailing year.

Where can I see OGN's full analysis?

Create a free Growth Stock Analyzer account to see where OGN ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.

Want the method behind the score? Read how we grade growth stocks with CANSLIM.

More growth stocks in Pharmaceutical Preparations